Session title
Transforming Emergency Care with Point of Care hs-TnI and Traumatic Brain Injury Markers
Presentation 1 Synopsis
Hosted by Dr. Lisa Braganza, Medical Affairs Director at Abbott, this dynamic symposium explores how point-of-care high sensitivity troponin I (hs-TnI) testing could help reshape emergency department workflows across Australia. With mounting pressure on EDs to reduce access block and length of stay, the Abbott i-STAT hs-TnI cartridge offers a breakthrough in rapid cardiac triage.
Join us as we explore share real-world pilot data, discuss integration strategies, and debate the future of bedside diagnostics. From faster decision-making to improved patient outcomes, this session will highlight why “minutes matter” in emergency cardiac care—and how point-of-care testing is delivering those minutes back to clinicians.
Presentation 2 Synopsis
Blunt trauma to the head or head injury is a common complaint among patients presenting to emergency departments. Computed tomography (CT) scans of the brain are highly accurate for the diagnosis or exclusion of fractured skull or intracranial bleeding after trauma. However, they are not without harms including radiation exposure, cost and hospital emergency department delays. Blood biomarkers may enable the exclusion of acute traumatic lesions without the need for imaging. The aim of this study is to validate GFAP+UCH-L1 as reported by Abbotts’s Alinity-I platform for excluding acute intracranial lesions among patients presenting with a Glasgow Coma Scale (GCS) of 13-15 after head injury. It is hypothesised that patients with GCS 13-15 and levels of GFAP and UCH-L1 below pre-specified threshold ding on CTB. We enrolled 850 patients and compared paired results of GFAP and UCH-L1 levels and results of CTB. The negative predictive value of the test with additional tests of diagnosis will be presented.
Speakers:
GFAP and UCH-L1 to exclude acute intracranial lesions after TBI- the initial Australian experience
Professor Biswadev Mitra